Duloxetine in the treatment of generalized anxiety disorder by Norman, Trevor R & Olver, James S
© 2008 Dove Medical Press Limited.   All rights reserved
Neuropsychiatric Disease and Treatment 2008:4(6) 1169–1180 1169
EXPERT OPINION
Duloxetine in the treatment of generalized 
anxiety disorder
Trevor R Norman
James S Olver
Department of Psychiatry, University 
of Melbourne, Austin Hospital, 
Heidelberg, Victoria, Australia
Correspondence: Trevor Norman
Department of Psychiatry, University 
of Melbourne, Austin Hospital, Heidelberg, 
3084, Victoria, Australia
Email trevorrn@unimelb.edu.au
Abstract: Duloxetine, a medication with effects on both serotonin and noradrenaline transporter 
molecules, has recently been approved for the treatment of generalized anxiety disorder. The 
evidence for its efﬁ  cacy lies in a limited number of double blind, placebo controlled comparisons. 
Statistically signiﬁ  cant improvements in the Hamilton Anxiety Rating Scale from baseline were 
demonstrated in all studies at doses of 60 to 120 mg per day. The signiﬁ  cance of such changes 
in terms of clinical improvements compared to placebo is less certain, particularly when the 
effect size of the change is calculated. In comparative trials with venlafaxine, duloxetine was 
as effective in providing relief of anxiety symptoms. In addition to improvements in clinical 
symptoms duloxetine has also been associated with restitution of role function as measured by 
disability scales. Duloxetine use is associated with nausea, dizziness, dry mouth, constipation, 
insomnia, somnolence, hyperhidrosis, decreased libido and vomiting. These treatment emergent 
side effects were generally of mild to moderate severity and were tolerated over time. Using 
a tapered withdrawal schedule over two weeks in the clinical trials, duloxetine was associated 
with only a mild withdrawal syndrome in up to about 30% of patients compared to about 17% 
in placebo treated patients. Duloxetine in doses of up to 200 mg twice daily did not prolong 
the QTc interval in healthy volunteers. Like other agents with dual neurotransmitter actions 
duloxetine reduces the symptoms of generalized anxiety disorder in short term treatments. 
Further evidence for its efﬁ  cacy and safety in long term treatment is required.
Keywords: duloxetine, generalized anxiety disorder, Hamilton anxiety rating scale, withdrawal 
syndrome, psycho-social function
Introduction
Generalized anxiety disorder (GAD) is a diagnosis of relatively recent origin (Tyrer 
and Baldwin 2006). The term anxiety neurosis, as deﬁ  ned by Freud, was used prior 
to 1980 to describe a condition characterized predominantly as feelings of unattached 
fearfulness. With the publication of the Diagnostic and Statistical Manual of Mental 
Disorders, Third Edition (DSM-III) anxiety neurosis was abandoned and GAD was 
introduced and distinguished from panic disorder. Under this rubric the diagnosis 
required that symptoms from three of four categories (motor tension, autonomic 
hyperactivity, apprehensive expectation, hyper-vigilance and scanning) to be pres-
ent for at least 1 month. Under DSM-III GAD was essentially a residual diagnostic 
category. Modiﬁ  cations to the diagnostic schemata as in the publication of the revised 
edition of DSM-III (DSM-III-R), deﬁ  ned GAD as being characterized by chronic 
(more than 6 months), persistent, generalized anxiety not meeting criteria for panic 
disorder, phobic disorder or obsessive-compulsive disorder. Following evidence that 
GAD can exist independently of anxiety related to anticipation of a panic attack, 
exposure to a phobic stimulus or obsessional concern, DSM-III-R deﬁ  ned GAD by 
positive criteria related to unrealistic/excessive anxiety or worry about 2 or more life 
concerns and 6 of 18 physical symptoms including 9 autonomic symptom clusters. 
If another Axis I anxiety disorder was present, GAD could still be diagnosed if the Neuropsychiatric Disease and Treatment 2008:4(6) 1170
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anxiety/worry present was unrelated to it. DSM-IV further 
reﬁ  ned the diagnostic criteria of GAD by exclusion of auto-
nomic symptoms from the list of somatic concerns required 
for diagnosis because of the low endorsement rate of these 
symptoms. The core features of the current deﬁ  nition of GAD 
revolve around uncontrollable and excessive worry. The 
worries experienced by patients with GAD reliably cluster 
around themes of family, ﬁ  nances, work and personal illness 
(Sanderson and Barlow 1990).
The alternate ICD-10 classiﬁ  cation also recognises GAD 
as a separate disorder of chronic duration (6 months) but 
differs from DSM-IV with respect to the pervasiveness of 
the symptomatology. Thus ICD-10 does not require worry to 
be excessive or uncontrollable while there is an emphasis on 
autonomic hyper-arousal. Further a minimum of four symp-
toms from a list of 22 somatic symptoms must be present to 
meet diagnostic criteria.
The differences in diagnostic schemes lead to rather dif-
ferent estimates of prevalence depending on which one is used 
for diagnosis. Nevertheless various epidemiological studies, 
using the different criteria, suggest that GAD is a common 
psychiatric presentation with estimates of lifetime prevalence 
of 2.8% to 6.6% in the general population (Carter et al 2001; 
Kessler et al 2005). The 12-month prevalence of any anxiety 
disorder in the National Co-morbidity study conducted in 
9,282 adults in the United States was 18.1% (Kessler et al 
2005). In this cohort the 12-month prevalence for GAD was 
5.7%. This ﬁ  gure is in reasonably close agreement to a number 
of epidemiological studies conducted in the European com-
munity (Lieb et al 2005). The lifetime prevalence of GAD 
ranged from 0.1% to 18.7%, while 12-month prevalence was 
reported as 0.1% to 2.1%. Discrepancies between surveys can 
be accounted for by the different diagnostic criteria employed 
(DSM-III, DSM-IV or ICD-10) and the different instruments 
used to asses anxiety (CIDI or DIS in most studies). Where 
DSM-III criteria were employed prevalence is usually higher 
due to the shorter duration requirement. The antecedents of 
GAD are in all likelihood present in childhood but some 
studies suggest that the age of onset of the disorder is rare 
before the age of 20 years (Wittchen et al 1998; Lieb et al 
2000). The majority of cases present for treatment in adult-
hood between 35 and 45 years of age (Wittchen et al 2000; 
Yonkers et al 2000; Carter et al 2001). Furthermore GAD 
has been reported to be the most common anxiety disorder 
in adults aged more than 55 years (Carter et al 2001).
Guidelines for the treatment of GAD recommend psy-
chotherapy, pharmacotherapy or the combination of both 
(Anderson 2006). The NICE (National Institute of Clinical 
Excellence, UK) guidelines indicate that psychotherapy should 
be ﬁ  rst line treatment (NICE 2004). It is generally regarded 
that medication and psychotherapy are equally effective for 
acute treatment (Anderson 2006; Tyrer and Baldwin 2006). 
Indeed a meta-analysis of 35 studies showed that the effect 
size for cognitive behavior therapy (0.7) was similar to that 
for medications (0.6) (Gould et al 1997). Among the psy-
chotherapies there is some evidence that cognitive behavior 
therapy has a better outcome at 6-month follow-up than 
anxiety management or analytical psychotherapy (Durham 
et al 1994). In longer term treatment psychological treatments 
might be better than medications but there are few compara-
tive data. Improvement with cognitive behavior therapy can 
be maintained for up to 2 years (Kingdon et al 1996). In longer 
follow-ups (8–14 years), only about a third of patients make 
a good recovery (Durham et al 2003).
Considerations of the characteristics of GAD and the 
preferences of individual patients need to be taken into 
account when deciding treatments (Lam 2006). Particular 
issues pertaining to the clinical characteristics of GAD are 
the waxing and waning course of the illness, its chronicity 
and co-morbidity with other psychiatric and non-psychiatric 
disorders. Additionally prospective data suggest that GAD has 
a relatively low rate of remission. Thus in the Harvard-Brown 
Anxiety Research program (HARP) the probability of remis-
sion was 0.38 at 5 years (Yonkers et al 2000). In the 5-year 
follow-up period 38% of patients achieved a full remission, 
ie, a consecutive 8-week period with no or only occasional 
symptoms. The prognosis must be regarded as unfavorable.
Patients with GAD commonly present with a co-existing 
depressive disorder (Baldwin and Polkinghorn 2005). Indeed 
based on the results of the National Co-morbidity Survey 
(Kessler et al 1994) it might be stated that co-morbidity is 
the rule rather than the exception. For GAD the total lifetime 
co-morbidity with another psychiatric diagnosis was 90.4% 
and the 30-day co-morbidity was 66.3% with the following 
disorders: mania, major depression, dysthymia, panic disor-
der and phobic disorders, alcohol or drug abuse (Wittchen 
et al 1994). This high co-morbidity has been used to suggest 
that GAD may be a residual or prodrome of another disorder 
(Wittchen et al 1994). On the other hand about a third of 
subjects with a current diagnosis of GAD did not have any 
other recent diagnosis in the National Co-morbidity study, 
which argued for GAD as an independent diagnostic category 
(Wittchen et al 1994).
For the short term treatment of GAD benzodiazepines have 
been shown to be more effective than placebo (Shader and 
Greenblatt 1993; Ballenger 2001; Davidson 2001; Baldwin Neuropsychiatric Disease and Treatment 2008:4(6) 1171
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and Polkhinghorn 2005). A statistically signiﬁ  cant effect size 
(Cohen’s d = 0.38 ± 0.15; p  0.0001) was noted for the ben-
zodiazepines compared to placebo in the treatment of GAD 
using meta-analysis (Hidalgo et al 2007). However, concerns 
about their long term use, particularly issues of tolerance and 
dependence, have seen a general reluctance to use benzodi-
azepines in clinical practice (Schweizer and Rickels 1998). 
Antidepressant medications have been extensively used in 
the treatment of various anxiety disorders and the evidence 
for their efﬁ  cacy in panic disorder, obsessive compulsive 
disorder and to a lesser extent in social anxiety disorder is well 
documented (Gorman 2002). More recently the effectiveness 
of antidepressants in GAD has been evaluated in a number of 
double-blind, placebo controlled clinical trials. The efﬁ  cacy of 
the selective serotonin reuptake inhibitors (SSRIs) in GAD has 
been frequently canvassed (Baldwin and Polkinghorn 2005). 
Beyond the SSRIs interest has been shown in so called “dual 
acting” antidepressants, most recently duloxetine.
Pharmacolgy of duloxetine
Mechanism of action
Duloxetine ((+)-(S)-N-methyl-γ-(1-naphthalenyloxy)-
2-thiophene-propanamine) inhibits serotonin (5HT) and 
noradrenaline (NE) reuptake into nerve endings or slice 
preparations with the NE/5HT ratio between 2 and 9 both in 
vivo and in vitro (Kasamo et al 1996; Wong 1998). The drug 
has a high afﬁ  nity for human cloned serotonin and noradrena-
line transporters in vitro and is more potent than venlafaxine 
(Bymaster et al 2001). Duloxetine has low afﬁ  nity for a range 
of other serotonin, muscarinic, adrenergic and histaminer-
gic receptors and does not signiﬁ  cantly inhibit monoamine 
oxidase A or B activity (Bymaster et al 2001). Microdialysis 
studies of acute doses showed that duloxetine signiﬁ  cantly 
enhanced the release of extra-cellular levels of both serotonin 
and noradrenaline in the pre-frontal cortex and hypothalamus 
of drug naïve rats (Engelman et al 1995). On the other hand, 
an in vitro study in healthy volunteers are at odds with the 
animal data and suggest that at doses of 20 and 60 mg/day 
duloxetine was selective for serotonin reuptake inhibition 
(Turcotte et al 2001). At higher doses (80 and 120 mg/day) 
an effect on noradrenaline reuptake was evident (Vincent et al 
2004). The pharmacology of duloxetine implies that it is the 
effect on both serotonin and noradrenaline reuptake which 
may account for the antidepressant activity of the drug.
Pharmacokinetics
Duloxetine pharmacokinetics was determined after single 
and multiple oral doses in healthy volunteers. Duloxetine is 
administered as an enteric coated pellet formulation due to its 
acid lability (Bymaster et al 2005). The drug exhibited linear 
pharmacokinetics in healthy male volunteers who received 
20 mg twice daily with a dose escalation at weekly intervals 
to 30 and 40 mg twice daily (Sharma et al 2000). Steady state 
plasma concentrations were attained within 3 days for each 
dosing regimen in this study. The effect of food on the rate 
of absorption of duloxetine was investigated in 12 healthy 
female volunteers following a single oral dose of 40 mg 
(Skinner et al 2000). The subjects received the drug on 4 sepa-
rate occasions separated by one week: after an overnight fast; 
15 minutes after a high fat meal; at bedtime and again after 
an overnight fast. Both food and night time administration 
delayed the time to maximum concentration (by a mean of 
4 hours) but only bedtime administration reduced the extent 
of absorption (AUC decreased ∼18%). The effects of food 
were considered to be relatively modest. A median 2-hour lag 
time was apparent until absorption began (Tlag), with maximal 
plasma concentrations (Cmax) of duloxetine occurring about 
6 hours after the dose. The apparent volume of distribution 
of duloxetine is large. On repeated dosing the mean apparent 
volume of distribution for duloxetine was 1943 L with a range 
of 803 to 3531 L (Sharma et al 2000). In this study the mean 
apparent oral clearance was 114 L/h with a range of 44 to 
218 L/h (Sharma et al 2000). The data in young and elderly 
females after a single oral dose of 40 mg agree reasonably 
well with the data obtained for males (Skinner et al 2003). 
Thus the mean apparent clearance was 70.3 L/h and the mean 
apparent volume of distribution was 962 L in younger women 
(32–50 years). Age had no statistically signiﬁ  cant effect on 
these parameters in elderly women (65–77 years) with a mean 
clearance 52.9 L/h and mean volume of distribution 1077.9 L 
(Skinner et al 2003). Duloxetine is highly bound (90%) to 
proteins in human plasma, binding primarily to albumin and 
α1-acid glycoprotein. The interaction between duloxetine and 
other highly protein bound drugs has not been fully evalu-
ated. Plasma protein binding of duloxetine is not affected by 
renal or hepatic impairment. The mean elimination half-life 
of duloxetine is about 12 hours (range 7–27 hours) (Sharma 
et al 2000; Skinner et al 2003). Following single oral doses 
of 20, 40 or 60 mg and multiple oral doses of 20 or 40 mg for 
5 days there were no clinically signiﬁ  cant differences in the 
pharmacokinetics of Japanese and Caucasian subjects (Chan 
et al 2007). Similarly a retrospective comparison of phar-
macokinetic parameters obtained after single and multiple 
oral dosing with 60 mg in healthy Chinese volunteers were 
consistent with the data obtained for Japanese and Caucasian 
subjects (Tianmei et al 2007).Neuropsychiatric Disease and Treatment 2008:4(6) 1172
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Elimination of duloxetine is mainly through hepatic 
metabolism involving two P450 isozymes, CYP2D6 and 
CYP1A2. Biotransformation and disposition of dulox-
etine has been determined following oral administration 
of  14C-labeled duloxetine (Lantz et al 2003). Unchanged 
duloxetine comprised about 3% of the total radio-labeled 
material in plasma, indicating that it underwent extensive 
metabolism to numerous metabolites. The major biotrans-
formation pathways for duloxetine involve oxidation of the 
naphthyl ring followed by conjugation and further oxidation. 
Both CYP2D6 and CYP1A2 catalyze the oxidation of the 
naphthyl ring in vitro. Metabolites found in plasma include 
4-hydroxy duloxetine glucuronide and 5-hydroxy, 6-methoxy 
duloxetine sulphate. Many additional metabolites have been 
identiﬁ  ed in urine, some representing only minor pathways 
of elimination. Only trace (1% of the dose) amounts of 
unchanged duloxetine are present in the urine. Most (about 
70%) of the duloxetine dose appears in the urine as metabo-
lites of duloxetine; about 20% is excreted in the feces (Lantz 
et al 2003). As would be expected for a drug extensively 
metabolized by the liver, patients with hepatic impairment 
arising in the context of cirrhosis show alterations in single 
dose pharmacokinetics (Suri et al 2005). Following a single 
oral dose of 20 mg apparent plasma clearance was lower 
(24 versus 160 L/h) and systemic exposure (as measured by 
AUC values) was higher (775 versus 268 ng/h/mL) in the 
cirrhotic patients compared to healthy controls. For these 
same subjects mean elimination half life was 3 times longer 
(47.8 versus 13.5 h) in cirrhotic patients compared to healthy 
volunteers.
Use of duloxetine in generalized 
anxiety disorder
Pre-clinical data
Evidence for the use of antidepressants in the treatment of 
anxiety disorders, at least based on the available animal 
models, is not well supported (Borsini et al 2002). Many 
of the models are established on their ability to detect the 
activity of the benzodiazepines and may not be representative 
for other classes of agents. In the case of antidepressants two 
factors may mitigate against the chances of positive results: 
clinical effects are often observed with chronic administra-
tion whereas the animal models for the most part rely on 
acute effects; many antidepressants, at least initially, are 
anxiogenic. Pre-clinical evidence for the anxiolytic effect 
of duloxetine has been observed after chronic administra-
tion in one animal model of anxiety (Troelsen et al 2005). 
The effects of 21 days treatment with 10 mg/kg twice daily 
of duloxetine, citalopram, reboxetine and amitriptyline in the 
zero maze were compared to their effects after acute admin-
istration. None of the agents was anxiolytic in this test after 
acute doses and indeed there was evidence for anxiogenic 
effects of reboxetine, duloxetine and amitriptyline. Only 
chronic duloxetine administration produced an anxiolytic 
response dissociable from non-speciﬁ  c motor effects in this 
task. The anxiolytic effect was attributed to the reduction in 
the serotonin transporter protein in the cortex of mice treated 
with duloxetine.
Clinical data
Duloxetine was approved for the treatment of GAD by 
both the US Federal Drug Administration and the British 
authorities early in 2007. Despite this approval there are 
relatively little published data to support its use in this con-
dition, although a priori it would be expected to be effective 
given similar data for other “dual acting” compounds such 
as venlafaxine. It has been speculated that all SNRI anti-
depressants (venlafaxine, duloxetine, milnacipran) might 
have similar efﬁ  cacy across a range of conditions including 
depression, chronic pain, PTSD, panic disorder and social 
anxiety disorder (Stahl et al 2005; Baldwin 2006).
Among the ﬁ  rst indications that duloxetine might be suit-
able for the treatment of anxiety symptoms was an analysis of 
its effect in trials of major depressive disorder (Dunner et al 
2003). Four placebo controlled trials were evaluated and its 
potential anxiolytic effect assessed from the changes on the 
anxiety/somatization factor and psychic anxiety (item 10) of 
the Hamilton Depression Rating Scale (HAM-D). In two of 
the studies (Goldstein et al 2002; Goldstein et al 2004), data 
from the Hamilton Anxiety Rating Scale (HAM-A) were also 
available. Within the limitations of the data set (exclusion 
of patients with primary anxiety disorder in past 12 months) 
duloxetine was more effective than placebo in alleviating 
anxiety symptoms in these depressed patients. The dose of 
duloxetine ranged from 40 to 120 mg/day. The study could 
not assess whether the effect on anxiety symptoms occurred 
independently of the effect on the symptoms of depression. In 
this pooled comparison duloxetine was also noted to be more 
effective than either of the comparator agents, paroxetine 
and ﬂ  uoxetine. For both comparator agents the dose was 
ﬁ  xed and the number of patients was smaller than the total 
number of patients treated with either duloxetine or placebo. 
The possibility that the result arises because of a statistical 
artefact cannot be overlooked.
Recent clinical trials have investigated the efﬁ  cacy of 
duloxetine for the treatment of patients with GAD. Each of the Neuropsychiatric Disease and Treatment 2008:4(6) 1173
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studies used similar diagnostic criteria (DSM-IV determined 
using the Mini International Neuropsychiatric Interview) to 
ensure that patients met criteria for GAD only. In particular 
patients were excluded if they met criteria for a recent (within 
the past 6 months) Major Depressive Disorder or substance 
abuse. A history within the past year of panic disorder, 
posttraumatic stress disorder or eating disorder was also an 
exclusion criterion. Thus patients who were included in the 
study may have had a lifetime co-morbidity of other mood 
disorders with GAD but not a current co-morbidity. A life-
time history of psychotic, bipolar or obsessive compulsive 
disorders was an additional diagnostic exclusion criterion. 
To ensure that anxiety symptoms predominated the clinical 
picture patients were required to have a Covi Anxiety score 
(CAS) 9 and no item in the Raskin Depression Scale 3 at 
baseline. Furthermore patients with an Axis II diagnosis were 
excluded from the studies. The studies and their main ﬁ  ndings 
are summarized in Table 1.
Duloxetine was compared to placebo in a 9-week, double-
blind, ﬂ  exible dose study in 513 patients meeting DSM-IV 
criteria for GAD (Koponen et al 2007). After a screening and 
washout phase of up to 30 days patients entered a single-blind, 
placebo phase of 1 week. An acute therapy phase of 9 weeks 
followed together with a 2-week discontinuation phase. 
Patients were randomly assigned to treatment with 60 mg 
once daily, 120 mg once daily duloxetine or placebo. The 
total HAM-A score was used in the assessment of efﬁ  cacy but 
did not form part of the entry criteria. However patients were 
stratiﬁ  ed according to HAM-A total scores  or 22 and 
were recruited from 42 outpatient clinics in 7 countries. 
Study visits were conducted at weeks 1, 2, 4, 6 and 9 of the 
double-blind treatment phase. Assessment of the efﬁ  cacy of 
treatments was based on the change in the total HAM-A score 
from baseline in addition to a number of secondary param-
eters: HAM-A psychic and somatic factors; Hospital Anxiety 
and Depression Scale (HADS); Patient and Clinician Global 
Impression-Improvements scales; Sheehan Disability Scale. 
For continuous efﬁ  cacy variables an analysis of covariance 
was used to assess change from baseline. In addition a mixed 
effects repeated measures analysis was performed to assess 
change over time. Statistically signiﬁ  cantly greater differ-
ences were observed for the reduction in anxiety symptoms 
in patients treated with either dose of duloxetine than for 
placebo (p  0.001). Differences in mean HAM-A scores 
from baseline were 4 points larger in duloxetine than in 
placebo treated patients. In this study the effect size could not 
be calculated as the variance in the HAM-A change scores 
was not reported. Based on a 50% reduction in HAM-A score 
from baseline, response rates were 58% for duloxetine 60 mg, 
56% for duloxetine 120 mg and 31% for placebo (p  0.001). 
Remission was deﬁ  ned as achieving a HAM-A score 7 at 
endpoint. Based on this criterion 31% of duloxetine 60 mg, 
38% duloxetine 120 mg and 19% of placebo treated patients 
achieved remission. There did not appear to be any clinical 
Table 1 Efﬁ  cacy of duloxetine in the treatment of generalized anxiety disorder: double-blind, placebo-controlled studies
Study Treatment Duration of 
treatment
Primary* 
outcome
Response rates**
DUL VEN PBO
Koponen et al 2007 60 mg/day DUL 9 weeks −12.8† 58% 31%
120 mg/day DUL −12.5 56%
PBO −8.4
Hartford et al 2007 60–120 mg/day DUL 10 weeks −11.8 (0.69) 47% 54% 37%
75–225 mg/day VEN −12.4 (0.67)
PBO −9.2 (0.67)
Rynn et al 2007 60–120 mg/day DUL 10 weeks −8.1† 40% 32%
PBO −5.9
Nicolini et al 2008 20 mg/day DUL 10 weeks −14.7 (1.0) 60% 61% 42%
60–120 mg/day DUL −15.3 (0.7) 65%
75–225 mg/day VEN −15.5 (0.7)
 PBO   −11.6 (0.7)    
*Mean change from baseline for the HAM-A score (SEM).
**Reduction in the baseline HAM-A score 50%.
†Variance measure not reported.
Abbreviations: DUL, duloxetine; PBO, placebo; VEN, venlafaxine.Neuropsychiatric Disease and Treatment 2008:4(6) 1174
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advantage for the higher dose of duloxetine, in terms of 
remission, over the lower dose. Statistically there were no 
differences between the two duloxetine doses for any of the 
efﬁ  cacy measures used. In all secondary efﬁ  cacy variables 
duloxetine 60 and 120 mg were superior to placebo statisti-
cally. Greater improvements in functioning were observed 
in both duloxetine groups compared to placebo (p  0.001) 
based on the change from baseline in the Sheehan Disability 
Scales. The data suggest that duloxetine attenuated the 
symptoms of GAD.
A similar double-blind, placebo-controlled trial of dulox-
etine was conducted in patients with a DSM-IV diagnosis 
of GAD over a 10-week period (Rynn et al 2007). Patients 
were recruited from 27 outpatient treatment centres in the 
US. To be eligible for the study, in addition to meeting DSM 
criteria, patients also had to meet certain severity criteria: 
Clinical Global Impression-Severity Scale (CGI-S) 4; 
Hospital Anxiety and Depression Scale (HADS) anxiety 
subscale 10; CAS 9; and CAS total Raskin Depression 
Scale. After a screening and washout phase of up to 30 days 
patients entered a single-blind, placebo phase of 1 week. 
An acute therapy phase of 10 weeks followed together with 
a 2-week discontinuation phase. The primary efﬁ  cacy mea-
sure was the HAM-A total score administered at each visit 
(weeks 1, 2, 4, 7 and 10). Secondary outcomes focused on 
improvements in overall symptom severity and global func-
tioning. A ﬂ  exible dosing schedule was adopted, such that 
a maximum of 120 mg/day of duloxetine could be attained. 
The primary efﬁ  cacy variable was the mean change from 
baseline to endpoint in the total HAMA-A score. Statistical 
differences were assessed using analysis of co-variance, 
while change over time was assessed with a mixed-effects 
repeated measures method. A total of 168 patients treated 
with duloxetine and 159 treated with placebo were included 
in the statistical analyses. A statistically signiﬁ  cant differ-
ence between duloxetine and placebo was evident from 
week 2 of treatment (p  0.001). Statistically signiﬁ  cant 
differences were evident at endpoint for the change in total 
HAM-A scores observed in duloxetine (8.12) and placebo 
(5.89) treated patients (p  0.05). Similar or greater differ-
ences were observed for the HAM-A factors and items. It 
was not possible to calculate an effect size for this study as 
the variance in the change scores was not reported. Based 
on the mean changes in the HAM-A score compared to that 
of the previous study, the effect of duloxetine did not appear 
to be as robust. Response, deﬁ  ned as a 50% reduction 
in HAM-A score from baseline, was 40% for duloxetine 
and 32% for placebo (p  0.05). However for remission, 
a HAM-A score at endpoint 7, there was no statistically 
signiﬁ  cant difference between duloxetine (28%) and placebo 
(23%). The mean ﬁ  nal dose of duloxetine at endpoint was 
101.9 mg/day with the majority of patients (58%) achieving 
120 mg/day. Despite the opportunity in this study to examine 
dose response effects for duloxetine such an analysis was not 
undertaken. The study suggests that duloxetine may possess 
a modest efﬁ  cacy in the short term treatment of GAD.
Duloxetine 60 to 120 mg/day was compared to venlafaxine 
XR (75–225 mg/day) and placebo over 10 weeks in adult 
patients meeting the DSM-IV criteria for the disorder 
(Hartford et al 2007). Almost 500 patients were randomly 
assigned to duloxetine (n = 160), venlafaxine XR (n = 164) 
or placebo (n = 161) and the efﬁ  cacy was assessed by the 
change in the HAM-A Rating score from baseline to end 
point. For the evaluation of statistical signiﬁ  cance of change 
an analysis of covariance was used. Greater improvement was 
observed in both the duloxetine (p  0.01) and venlafaxine 
(p  0.001) groups than for the placebo treated patients. 
There were no statistically signiﬁ  cant differences between 
the duloxetine and venlafaxine groups. Cohen’s d was used 
to compute an effect for this trial based on the reported mean 
(and standard deviation) change from baseline in the HAM-A 
scores for patients in the three treatment arms. For duloxetine 
60 to 120 mg/day compared to placebo the Cohen’s d was 
0.30 (95% conﬁ  dence interval [CI] 0.08 to 0.52) and for 
venlafaxine 72 to 225 mg/day compared to placebo Cohen’s d 
was calculated as 0.37 (95% CI 0.15–0.59). These effect 
sizes are similar to those reported in a recent meta-analysis 
for antidepressant treatment of GAD (Hidalgo et al 2007). 
For the comparison of duloxetine and venlafaxine Cohen’s d 
was 0.07 (95% CI –0.15 to 0.29), suggesting no difference in 
efﬁ  cacy between the two drugs. Discontinuation of treatment 
for adverse events was greater in the duloxetine (14.2%) and 
venlafaxine (11.0%) groups than for placebo group (1.9%). 
On the other hand the overall rate of discontinuation for 
any reason was not different for the three groups. Following 
tapering of the medication over a 2-week period at the end 
of the trial there were signiﬁ  cantly more emergent adverse 
events for venlafaxine treated patients (26.9%) than for either 
duloxetine (19.4%) or for placebo (15.8%). Duloxetine was 
equivalent to venlafaxine in the symptomatic relief of GAD 
and both provided greater relief than placebo.
A further comparative study of duloxetine and venlafaxine 
was performed in 33 non-US sites (Nicolini et al 2008). 
Diagnostic criteria were substantially the same as those used 
in the previous trials with the HAM-A scale as the primary 
efﬁ  cacy measure. Secondary efﬁ  cacy measures were assessed Neuropsychiatric Disease and Treatment 2008:4(6) 1175
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from the psychic and somatic anxiety factors scores of the 
HAM-A, Sheehan Disability Scale, HADS, CGI-I and the 
Patient Global Impression Improvement (PGI-I) scales. 
Patients completed a 3- to 30-day screening phase and then 
were randomly assigned to duloxetine 20 mg once daily, 
duloxetine 60 to 120 mg once daily, venlafaxine 75 to 225 mg 
once daily or placebo. For the higher duloxetine dose group 
and for venlafaxine the dose was titrated according to 
response throughout the 10-week treatment period. Statistical 
analyses were conducted on the intent to treat population. The 
primary efﬁ  cacy analysis was the change from baseline in the 
HAM-A total score, which was compared between treatment 
groups using an analysis of covariance (ANCOVA) model 
with treatment and investigator as ﬁ  xed effects and baseline 
score as a covariate. A mixed model repeated measures 
analysis was also performed. Based on the LOCF and mixed 
models analyses all three active treatment groups demon-
strated a statistically signiﬁ  cant difference from placebo in 
reducing the HAM-A total score (duloxetine 20 mg versus 
placebo p  0.01; duloxetine 60–120 mg and venlafaxine 
versus placebo p  0.001). Similar results were also obtained 
for psychic and somatic anxiety factors. For effect size calcu-
lations Cohen’s d was used. For the comparison of duloxetine 
20 mg and placebo d was 0.34 (95% CI 0.08–0.61) and for 
duloxetine 60 to 120 mg and placebo d was 0.42 (95% CI 
0.20–0.62). Both effect sizes were similar to that which could 
be calculated for the comparison of venlafaxine and placebo 
(d = 0.44; 95% CI 0.22–0.66). There were no differences 
between venlafaxine and duloxetine 20 mg/day (d = 0.09; 
95% CI –0.18 to 0.36) or duloxetine 60 to 120 mg/day 
(d = 0.02; 95% CI –0.20 to 0.25) based on the calculation 
of Cohen’s d. Similarly duloxetine 20 mg and duloxetine 
60 to 120 mg were not different (d = 0.07; 95% CI –0.20 to 
0.34). Again the study provides evidence for the efﬁ  cacy of 
duloxetine in the treatment of GAD at least as effective as 
venlafaxine.
Duloxetine was compared to venlafaxine in adult patients 
with GAD using non-inferiority criteria (Allgulander et al 
2008). In this report data from two previous trials (see Hartford 
et al 2007; Nicolini et al 2008) were combined and six non-
inferiority criteria were established by an independent (of the 
pharmaceutical manufacturer) panel of experts. The consen-
sus panel’s recommendations for non-inferiority are noted in 
Table 2. The ﬁ  rst four criteria needed to be satisﬁ  ed before 
the last two were considered. The statistical analysis used 
the HAM-A score as the primary outcome measure while the 
non-inferiority analyses used a lower bound of a one-sided 
97.5% conﬁ  dence interval for the difference between the test 
intervention and reference intervention as recommended by 
the International Committee on Harmonization (ICH 1998). 
The primary analysis was conducted on the per-protocol 
patients who were treated with duloxetine (n = 239) or ven-
lafaxine XR (n = 262). The per-protocol sample was deﬁ  ned 
as patients who had completed at least 4 weeks of treatment, 
had baseline and post-baseline HAM-A ratings after at least 
4 weeks of treatment, and did not have any protocol viola-
tions that were judged to potentially have an impact on the 
analysis or conclusions. Duloxetine 60 to 120 mg/day met all 
statistical and clinical criteria for non-inferiority with a mean 
difference in HAM-A total score improvements between 
duloxetine and placebo of −3.8, compared to the differ-
ence between venlafaxine XR and placebo of −3.6 points. 
Subtracting the two drug-placebo mean differences yielded 
a point estimate of 0.20 HAM-A total score points in favor 
of duloxetine. The lower bound of the conﬁ  dence interval 
for this point estimate was −1.28 in the per-protocol sample 
which was within the pre-speciﬁ  ed −1.5 margin. Thus the 
criterion for non-inferiority was met. Response rates for 
duloxetine, venlafaxine XR, and placebo were 56%, 58% 
and 40%, respectively.
A further pooled analysis of data from the four clinical 
trials was performed to examine the efﬁ  cacy and tolerability 
Table 2 Non-inferiority criteria used for comparative analysis of duloxetine and venlafaxine in generalized anxiety disordera
1. At least one three-arm double-blind comparison trial for test intervention with an active comparator.
2.   Both the test intervention and the active comparator should be superior to placebo by a clinically meaningful difference in the HAM-A total score 
(set at 2 points by the panel).
3.   Treatment response rates (deﬁ  ned as 50% reduction in HAM-A total score from baseline to study end point) for the test and active comparator 
groups should be at least 10 percentage points greater than the response for placebo.
4.  Both the active and test intervention have to be statistically signiﬁ  cantly better than placebo on the primary outcome measure.
5.   The non-inferiority margin between the test intervention and the active comparator is 50% of the difference between active comparator and 
placebo, and this difference is not clinically meaningful.
6. The response rate of the test intervention is not more than 5 percentage points lower than the response rate in the active comparator group.
aFrom the pooled non-inferiority comparison reported by Allgulander et al 2008.Neuropsychiatric Disease and Treatment 2008:4(6) 1176
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of duloxetine in elderly patients (Davidson et al 2008). From 
the database there were 73 patients (45 randomly assigned 
to duloxetine and 28 to placebo) older than 65 years. This 
represented a relatively small proportion (4.9%) of the total 
population treated. Compared to placebo treated subjects, 
duloxetine treated patients had statistically signiﬁ  cantly 
greater improvements for the HAM-A total score (p  0.05) 
and psychic (p  0.05) but not somatic anxiety factors. Based 
on the reported change scores from baseline to endpoint 
of the total HAM-A scores Cohen’s d was calculated as 
0.56 (95% CI 0.04–1.02), which is within the range of that 
reported for other anxiolytic agents (Hidalgo et al 2007). 
In this patient population there were high discontinuation 
rates for adverse effects (22.2% for duloxetine versus 0% for 
placebo). Evaluations in populations of elderly patients are 
of further interest, particularly given that GAD is reputedly 
the most common anxiety disorder in adults aged 55 years 
or more (Carter et al 2001).
Two pooled analyses of the placebo arms of the con-
trolled trials were conducted to examine duloxetine efﬁ  cacy 
and effect on functional outcomes. Patients assigned to the 
venlafaxine arm of the Hartford et al (2007) study were not 
included in the pooled analysis. The pooled analysis gave 
a database of 668 patients treated with duloxetine 60 to 
120 mg/day and 495 patients treated with placebo for up to 
10 weeks. With respect to efﬁ  cacy, duloxetine-treated patients 
improved statistically signiﬁ  cantly more from baseline to 
endpoint than did placebo treated patients (11.1 points versus 
8.0 points on the HAMA-A scale; p  0.001; ANCOVA) 
(Allgulander et al 2007). The authors suggest that such 
improvements are clinically important representing a decline 
in baseline severity of anxiety by about a half. Remission of 
symptoms was attained by about a third of patients treated 
with duloxetine. Both psychic and somatic anxiety sub-scales 
of the HAM-A scale were improved. Using the data reported 
in this pooled analysis it was possible to calculate an effect 
size for baseline HAM-A scores as well as the treatment 
endpoint HAM-A scores. At baseline the effect size was 0.01 
(Cohen’s d = 0.02). The groups were well matched and not 
signiﬁ  cantly different. At end point the effect size was 0.18 
(Cohen’s d = 0.37). The effect of duloxetine in GAD can be 
regarded as relatively modest based on the pooled analysis 
particularly when compared to the effect sizes calculated in 
recent meta-analyses for antidepressants used in the treatment 
of GAD (Mitte et al 2005; Hidalgo et al 2007).
Along with the improvements in anxiety symptomatol-
ogy self-reported assessments of psycho-social function-
ing were also signiﬁ  cantly improved in a pooled analysis 
(Endicott et al 2007). In each of the three studies the Sheehan 
Disability Scale (SDS), including the subscales global func-
tioning, work/school life, social life and family home respon-
sibility, were measured and showed a fall to mild severity 
in the duloxetine treated patients compared to moderate 
severity in the placebo treated patients. For duloxetine-treated 
patients 47% achieved a SDS global score 5 (indicative 
of a normative range) compared to 28% of placebo treated 
patients. Duloxetine treated patients reported a greater 
improvement in their quality of life, as measured with the 
Quality of Life Enjoyment and Satisfaction Questionnaire 
Short Form (Q-LES-Q-SF), than did placebo treated patients 
(p  0.01; ANOVA). The data suggest that not only symp-
tomatic improvements are achieved by patients treated with 
duloxetine but that these improvements impact on social 
function and life satisfaction.
Safety and tolerability
Treatment-emergent side effects
Based on the pooled analysis of the three placebo controlled 
trials, discontinuation rates in patients receiving duloxetine 
due to adverse events was 15.6% compared to 4.2% for pla-
cebo (p  0.001) (Allgulander et al 2007). The most common 
side effects (5% incidence and twice the rate in placebo 
treated patients) were nausea, dizziness, dry mouth, con-
stipation, insomnia, somnolence, hyperhidrosis, decreased 
libido, vomiting and erectile dysfunction. For the majority of 
patients these side effects were rated as mild to moderate in 
intensity. These adverse events are similar to those reported in 
pooled analyses for the use of duloxetine in other conditions. 
For example, the tolerability of duloxetine, when used as a 
treatment for depression, was addressed in a pooled analysis 
from eight placebo controlled comparisons (Hudson et al 
2005). The data base represented 1139 patients treated with 
doses of duloxetine ranging from 40 to 120 mg/day for up to 
34 weeks in total. Nausea, dry mouth, constipation, insomnia, 
dizziness and fatigue were the main side effects reported in 
these studies and all occurred signiﬁ  cantly more frequently 
than with placebo. Cardiovascular assessments showed a 
slight increase in systolic and diastolic blood pressure as 
well as heart rate compared to placebo but were unlikely to 
be clinically signiﬁ  cant. The incidence of abnormal labora-
tory parameters was generally similar between placebo and 
duloxetine treated patients. Most notably there were increases 
in liver enzyme values in patients treated with duloxetine, 
but the changes were not regarded as clinically important. 
There were 3 deaths in duloxetine-treated patients: 1 due 
to suicide, 1 due to cardiorespiratory arrest and the other to Neuropsychiatric Disease and Treatment 2008:4(6) 1177
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non-cardiogenic pulmonary edema. A series of 4 case reports 
suggesting a close temporal relationship between duloxetine 
use and the emergence of suicidal ideation in adult patients 
has been reported (Parikh et al 2008). In each of the cases 
suicidal ideation emerged in the context of increasing the 
dose of duloxetine. These ideas resolved when duloxetine 
was stopped.
Another pooled analysis was performed on the tolerability 
data for 23,983 patients exposed to duloxetine in 64 studies 
for any indication, including GAD (Gahimer et al 2007). 
The most common treatment emergent adverse events were 
nausea, headache, dizziness, dry mouth, constipation, insom-
nia, somnolence, hyperhidrosis, diarrhea and fatigue. These 
effects were reported to emerge early in treatment and were 
of mild to moderate severity. Generally they were tolerated 
with time. Increases in systolic and diastolic blood pressure 
on average were 1 mmHg.
It can be concluded for these analyses that duloxetine 
at the doses used results in side effects consistent with 
the known pharmacological proﬁ  le of the drug. In general 
the compound is well tolerated by most patients, at least in 
the short term. Some information on long term safety is avail-
able from studies in depression. An open label extension of 
duloxetine in doses of 60 to 120 mg/day was conducted in 
81 patients with major depressive disorder for up to two years 
of treatment (Wohlreich et al 2007). Treatment emergent side 
effects included upper respiratory tract infection (13.1%), 
headache (10.7%), insomnia (10.7%), anxiety (9.5%), weight 
gain (9.5%), nasopharyngitis (8.3%), constipation (7.1%), 
hyperhidrosis (7.1%) and abnormal dreams (6.0%). Both 
diastolic and systolic blood pressure were increased by about 
1 mmHg and heart rate was increased by a mean of about 
3 bpm. The data suggest that duloxetine is not associated with 
major side effects on long term administration. Nevertheless 
the database is relatively small. Further data on the longer 
term use of the drug and its safety and tolerability in patients 
with GAD are required.
Cardiovascular and electrocardiographic 
effects
Of growing concern in the use of many medications has been 
the risk of sudden cardiac death associated with prolongation 
of the corrected QT interval (QTc) (Fermini and Fossa 2003). 
The effects of supra-therapeutic exposures to duloxetine were 
evaluated in 117 healthy female volunteers using a random-
ized, double-blind, placebo controlled, cross-over study 
(Zhang et al 2007). Subjects received placebo for 22 days or 
duloxetine for 20 days with a 14 day washout period between 
regimens. In addition each subject received a single oral dose 
of  400 mg moxiﬂ  oxacin before or after the placebo/duloxetine 
treatment as a positive control. Duloxetine was administered 
to a maximum dose level of 200 mg twice daily using a 
step-wise dose escalation procedure. ECG was recorded at 
four time points (2, 6, 10 and 12 hours) at baseline, fourth 
day of duloxetine dosing, and at the two highest dose levels 
(160 mg bd and 200 mg bd). Following moxiﬂ  oxacin ECG 
was recorded 2 and 6 hours after dosing. Data were analyzed 
using 3 QT interval correction methods: mixed effects analysis 
of covariance with RR interval change from baseline as the 
covariate, Fridericia’s correction method and an individual QT 
correction method. The mean QTc interval was not prolonged 
for any of the three correction methods. On the contrary mean 
QTc interval decreased from baseline. Moxiﬂ  oxacin prolonged 
QTc at all time points regardless of the correction method. 
Duloxetine at supra-therapeutic doses is unlikely to affect the 
QT interval in healthy subjects. These ﬁ  ndings are consistent 
with the data obtained in clinical trials where mean change in 
the QRS width of the electrocardiogram was judged not likely 
to be of clinical signiﬁ  cance (Hudson et al 2005). A further 
evaluation of the cardiovascular safety of duloxetine was 
performed based on all patients exposed to the drug in clinical 
trials up to December 2005 (Wericke et al 2007). A total of 
8504 patients from 42 trials were included in the analysis. The 
safety proﬁ  le was based on vital signs, ECGs and emergent 
events potentially related to cardiovascular effects of the drug. 
Duloxetine treated patients were more likely than placebo 
treated patients to have increases in heart rate and decreases 
in QTc (Fridericia’s correction) interval. However none of 
the changes observed were regarded as clinically signiﬁ  cant. 
Only one duloxetine treated patient had a prolongation of 
the QTc interval to 500 msecs (from 499 msecs at base-
line to 514 msecs at maximum post baseline observation). 
In duloxetine-treated patients mean increase in systolic and 
diastolic blood pressure was 0.65 mmHg and 0.88 mmHg 
respectively. There was no evidence for a sustained increase 
in blood pressure associated with the use of duloxetine. 
Cardiovascular-related adverse events such as palpitations, 
tachycardia, orthostatic hypotension, hypertension and 
peripheral edema occurred in duloxetine treated patients to 
about the same extent as in placebo treated patients. With the 
exception of palpitations (1.5% for duloxetine treated patients) 
these events occurred with a frequency less than 1%.
Discontinuation events
In the placebo controlled studies evidence for discontinu-
ation effects following cessation of duloxetine was sought Neuropsychiatric Disease and Treatment 2008:4(6) 1178
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during a two-week tapering of the medication. There was 
no difference in the proportion of patients experiencing any 
event between duloxetine and placebo groups (Allulgander 
et al 2007). Dizziness, headache and insomnia all occurred 
more frequently with duloxetine, whereas upper respiratory 
infection occurred more frequently with placebo. In the trials 
discontinuation events were noted in 19.4% to 31.1% of 
duloxetine-treated patients and 15.8% to 17.3% of placebo-
treated patients. In none of the trials was the difference 
between duloxetine and placebo statistically signiﬁ  cant. There 
did not appear to be any difference in the frequency of with-
drawal symptoms depending on the dose of duloxetine.
Following abrupt discontinuation in depression trails 
there was no evidence of a severe withdrawal syndrome 
(Hudson et al 2005). Despite this it is recommended that the 
drug be tapered on withdrawal from treatment.
Conclusions
These studies in relatively large populations of patients 
provide reasonable evidence of the efﬁ  cacy of duloxetine 
as a short term treatment for GAD. There were signiﬁ  cant 
reductions in the baseline scores in the HAM-A scale during 
treatment for up to 10 weeks with the drug. Some 50% to 60% 
of patients achieved a 50% reduction in their initial scores. 
In addition to symptomatic relief signiﬁ  cant improvements 
in role functioning and quality of life were also attained by 
patients treated with duloxetine in comparison to placebo. 
At the doses used the drug is associated with some side 
effects which are generally predictable based on the known 
pharmacology of the agent. On the whole the side effects 
were of mild to moderate severity and were well tolerated, 
tending to diminish in intensity over time. With respect to 
cardiovascular safety a speciﬁ  c study evaluated effects on the 
QT interval at doses above those recommended for treatment 
of GAD and found no clinically signiﬁ  cant prolongation of 
the interval. However this study was conducted in otherwise 
healthy volunteers and does not ensure the cardiac safety in 
patients with an already compromised system (eg, previ-
ous myocardial infarction, heart failure). Concerns about a 
potential withdrawal syndrome concluded that there may be 
a mild syndrome provided the drug is tapered during discon-
tinuation. Abrupt withdrawal may also be a safe procedure, 
but there is little data with which to conﬁ  dently assert this 
conclusion. Clearly, further work is necessary to address the 
issues of duloxetine long term safety and efﬁ  cacy, at least 
for patients with a diagnosis of GAD.
Of note with all of the papers reviewed here is the poten-
tial for a conﬂ  ict of interest of the authors. A recent analysis 
has suggested that both industry sponsorship and author 
conﬂ  ict of interest affect study outcomes (Perlis et al 2005). 
While potential conﬂ  icts of interest do not imply unethical 
behavior or wrongdoing, the possibility of the publication of 
more favorable results exists. In the studies reviewed there is 
a noticeable involvement of employees of the manufacturer 
of duloxetine in the authorship of the papers. It is not clearly 
delineated what role these particular authors had in the ﬁ  nal 
content of the papers and whether that involvement extended 
beyond statistical advice and provision of the raw data. This is 
not to imply that papers reviewed were unsound, either from 
the clinical or statistical methodology used, on the contrary 
this was exemplary. While ideally clinical evaluations of 
medicines should be conducted independently of the manu-
facturer it is recognized that costs of clinical trials are now 
beyond the scope of individual investigators. Nevertheless, 
for various reasons, the issues of ﬁ  nancial conﬂ  ict of inter-
est have been shown to inﬂ  uence the reporting of such trials 
(Healy and Cattell 2003). Furthermore, when published clini-
cal trial data are compared with that held in databases which 
include unpublished data there is a tendency for the efﬁ  cacy 
of drugs to be inﬂ  ated (Turner et al 2008). We are not aware 
of any unpublished or failed trials of duloxetine in GAD at 
the time of publication which might inﬂ  uence the conclusions 
about the efﬁ  cacy of drug.
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